Journal of Clinical Oncology, Vol 19, Issue 1
(January), 2001: 265-272
© 2001 American Society for Clinical Oncology
Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?
By Edward L. Korn,
Susan G. Arbuck,
James M. Pluda,
Richard Simon,
Richard S. Kaplan,
Michaele C. Christian
From the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.
Address reprint requests to Edward L. Korn, PhD, Biometric Research Branch, EPN-739, National Cancer Institute, Bethesda, MD 20892; email korne{at}ctep.nci.nih.gov
ABSTRACT: Preclinical data suggest that some new anticancer agents directed at novel targets demonstrate tumor growth inhibition but not tumor shrinkage. Such cytostatic agents may offer clinical benefits for patients in the absence of tumor shrinkage. In addition, lower doses of some of these agents may be just as effective as higher doses, implying that toxicity may not be an ideal end point for dose finding. Because of these factors, the sequence and design of traditional phase I, II, and III trials used for cytotoxic agents (which typically shrink tumors and in a dose-dependent manner) may not be appropriate for cytostatic agents. This article discusses options for modifying trial designs to accommodate cytostatic agents. Examples are given where these options have been tried or are currently being tried. Recommendations given for choosing among the trial designs depend on what is known preclinically about the agents (eg, does one have a validated and reproducible biologic end point that can be used to guide a dose escalation?), what is known about the patient population being studied (eg, does one have a well-documented historical progression-free survival rate at 1 year for comparison with the experience of the new agent?), and the numbers of agents and patients available for participation in trials. Planned and ongoing trials will test the utility of some of these new approaches.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
S. A. Cannistra
Phase II Trials in Journal of Clinical Oncology
J. Clin. Oncol.,
July 1, 2009;
27(19):
3073 - 3076.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Natale, D. Bodkin, R. Govindan, B. G. Sleckman, N. A. Rizvi, A. Capo, P. Germonpre, W. E.E. Eberhardt, P. K. Stockman, S. J. Kennedy, et al.
Vandetanib Versus Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study
J. Clin. Oncol.,
May 20, 2009;
27(15):
2523 - 2529.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Le Tourneau, J. J. Lee, and L. L. Siu
Dose Escalation Methods in Phase I Cancer Clinical Trials
J Natl Cancer Inst,
May 20, 2009;
101(10):
708 - 720.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Rubinstein, J. Crowley, P. Ivy, M. LeBlanc, and D. Sargent
Randomized Phase II Designs
Clin. Cancer Res.,
March 15, 2009;
15(6):
1883 - 1890.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Resche-Rigon, S. Zohar, and S. Chevret
Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes
Clinical Trials,
December 1, 2008;
5(6):
595 - 606.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Zohar, Qing Lian, V. Levy, K. Cheung, A. Ivanova, and S. Chevret
Quality assessment of phase I dose-finding cancer trials: proposal of a checklist
Clinical Trials,
October 1, 2008;
5(5):
478 - 485.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. A. Eisenhauer and R. H. El-Maraghi
In Reply
J. Clin. Oncol.,
July 20, 2008;
26(21):
3654 - 3655.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Italiano, C. Massard, R. Bahleda, A.-L. Vataire, E. Deutsch, N. Magne, J.-P. Pignon, G. Vassal, J.-P. Armand, and J.-C. Soria
Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy
Ann. Onc.,
April 1, 2008;
19(4):
787 - 792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. R. Pond, L. L. Siu, M. Moore, A. Oza, H. W. Hirte, E. Winquist, G. Goss, G. Hudes, and C. A. Townsley
Nomograms to Predict Serious Adverse Events in Phase II Clinical Trials of Molecularly Targeted Agents
J. Clin. Oncol.,
March 10, 2008;
26(8):
1324 - 1330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H. El-Maraghi and E. A. Eisenhauer
Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
J. Clin. Oncol.,
March 10, 2008;
26(8):
1346 - 1354.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. L. Korn, P.-Y. Liu, S. J. Lee, J.-A. W. Chapman, D. Niedzwiecki, V. J. Suman, J. Moon, V. K. Sondak, M. B. Atkins, E. A. Eisenhauer, et al.
Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
J. Clin. Oncol.,
February 1, 2008;
26(4):
527 - 534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Grothey, E. E. Hedrick, R. D. Mass, S. Sarkar, S. Suzuki, R. K. Ramanathan, H. I. Hurwitz, R. M. Goldberg, and D. J. Sargent
Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107
J. Clin. Oncol.,
January 10, 2008;
26(2):
183 - 189.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Rixe and T. Fojo
Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient?
Clin. Cancer Res.,
December 15, 2007;
13(24):
7280 - 7287.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. V. Rubinstein, J. E. Dancey, E. L. Korn, M. A. Smith, and J. J. Wright
Early Average Change in Tumor Size in a Phase 2 Trial: Efficient Endpoint or False Promise?
J Natl Cancer Inst,
October 3, 2007;
99(19):
1422 - 1423.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Rademaker-Lakhai, L. V. Beerepoot, N. Mehra, S. A. Radema, R. van Maanen, J. S. Vermaat, E. O. Witteveen, C. M. Visseren-Grul, L. Musib, N. Enas, et al.
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C {beta}-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer
Clin. Cancer Res.,
August 1, 2007;
13(15):
4474 - 4481.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Escudier, N. Lassau, E. Angevin, J. C. Soria, L. Chami, M. Lamuraglia, E. Zafarana, V. Landreau, B. Schwartz, E. Brendel, et al.
Phase I Trial of Sorafenib in Combination with IFN {alpha}-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma
Clin. Cancer Res.,
March 15, 2007;
13(6):
1801 - 1809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kawada, K. Murakami, T. Sato, Y. Kojima, H. Ebi, H. Mukai, M. Tahara, K. Shimokata, and H. Minami
Prospective Study of Positron Emission Tomography for Evaluation of the Activity of Lapatinib, a Dual Inhibitor of the ErbB1 and ErbB2 Tyrosine Kinases, in Patients with Advanced Tumors
Jpn. J. Clin. Oncol.,
January 1, 2007;
37(1):
44 - 48.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Chanan-Khan, K. C. Miller, L. Musial, D. Lawrence, S. Padmanabhan, K. Takeshita, C. W. Porter, D. W. Goodrich, Z. P. Bernstein, P. Wallace, et al.
Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study
J. Clin. Oncol.,
December 1, 2006;
24(34):
5343 - 5349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Muruganandham, M. Lupu, J. P. Dyke, C. Matei, M. Linn, K. Packman, K. Kolinsky, B. Higgins, and J. A. Koutcher
Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T.
Mol. Cancer Ther.,
August 1, 2006;
5(8):
1950 - 1957.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Francart, C. Legrand, R. Sylvester, M. Van Glabbeke, J. P. van Meerbeeck, and A. Robert
Progression-Free Survival Rate As Primary End Point for Phase II Cancer Clinical Trials: Application to Mesothelioma--The EORTC Lung Cancer Group
J. Clin. Oncol.,
July 1, 2006;
24(19):
3007 - 3012.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Gray, J. Manola, S. Saxman, J. Wright, J. Dutcher, M. Atkins, M. Carducci, W. See, C. Sweeney, G. Liu, et al.
Phase II Clinical Trial Design: Methods in Translational Research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
Clin. Cancer Res.,
April 1, 2006;
12(7):
1966 - 1969.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. H. Estey
Statistical Considerations in Trials of Targeted Therapy: Acute Myelogenous Leukemia as an Example
Am. Assoc. Cancer Res. Educ. Book,
April 1, 2006;
2006(1):
289 - 292.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P. Lee, P. M. Patel, P. J. Selby, B. W. Hancock, I. Mak, L. Pyle, M. G. James, D. A. Beirne, S. Steeds, R. A'Hern, et al.
Randomized Phase II Study Comparing Thalidomide With Medroxyprogesterone Acetate in Patients With Metastatic Renal Cell Carcinoma
J. Clin. Oncol.,
February 20, 2006;
24(6):
898 - 903.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Vickers, J. Kuo, and B. R. Cassileth
Unconventional Anticancer Agents: A Systematic Review of Clinical Trials
J. Clin. Oncol.,
January 1, 2006;
24(1):
136 - 140.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. D. Rosa, J. Harris, and G. C. Jayson
The Best Guess Approach to Phase I Trial Design
J. Clin. Oncol.,
January 1, 2006;
24(1):
206 - 208.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. V. Rubinstein, E. L. Korn, B. Freidlin, S. Hunsberger, S. P. Ivy, and M. A. Smith
Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening Trials
J. Clin. Oncol.,
October 1, 2005;
23(28):
7199 - 7206.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Liu, H. S. Rugo, G. Wilding, T. M. McShane, J. L. Evelhoch, C. Ng, E. Jackson, F. Kelcz, B. M. Yeh, F. T. Lee Jr, et al.
Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Pharmacodynamic Measure of Response After Acute Dosing of AG-013736, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors: Results From a Phase I Study
J. Clin. Oncol.,
August 20, 2005;
23(24):
5464 - 5473.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Freidlin and R. Simon
Evaluation of Randomized Discontinuation Design
J. Clin. Oncol.,
August 1, 2005;
23(22):
5094 - 5098.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Fingleton
Learning from Our Mistakes: The Translation of MMPIs from Laboratory to Clinical Trial
Am. Assoc. Cancer Res. Educ. Book,
April 1, 2005;
2005(1):
30 - 32.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Messmann
Patient Selection for Early Phase Clinical Trials
Am. Assoc. Cancer Res. Educ. Book,
April 1, 2005;
2005(1):
294 - 296.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Hicklin and L. M. Ellis
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
J. Clin. Oncol.,
February 10, 2005;
23(5):
1011 - 1027.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Anderson, P. C. Adamson, S. L. Weiner, M. S. McCabe, and M. A. Smith
Tissue Collection for Correlative Studies in Childhood Cancer Clinical Trials: Ethical Considerations and Special Imperatives
J. Clin. Oncol.,
December 1, 2004;
22(23):
4846 - 4850.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. G. Roberts Jr, B. H. Goulart, L. Squitieri, S. C. Stallings, E. F. Halpern, B. A. Chabner, G. S. Gazelle, S. N. Finkelstein, and J. W. Clark
Trends in the Risks and Benefits to Patients With Cancer Participating in Phase 1 Clinical Trials
JAMA,
November 3, 2004;
292(17):
2130 - 2140.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Camphausen, T. Scott, M. Sproull, and P. J. Tofilon
Enhancement of Xenograft Tumor Radiosensitivity by the Histone Deacetylase Inhibitor MS-275 and Correlation with Histone Hyperacetylation
Clin. Cancer Res.,
September 15, 2004;
10(18):
6066 - 6071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. V. Heymach, J. Desai, J. Manola, D. W. Davis, D. J. McConkey, D. Harmon, D. P. Ryan, G. Goss, T. Quigley, A. D. Van den Abbeele, et al.
Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas
Clin. Cancer Res.,
September 1, 2004;
10(17):
5732 - 5740.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. V. Heymach, D. H. Johnson, F. R. Khuri, H. Safran, L. L. Schlabach, F. Yunus, R. F. DeVore III, P. M. De Porre, H. M. Richards, X. Jia, et al.
Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer
Ann. Onc.,
August 1, 2004;
15(8):
1187 - 1193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. L. Korn
Nontoxicity Endpoints in Phase I Trial Designs for Targeted, Non-Cytotoxic Agents
J Natl Cancer Inst,
July 7, 2004;
96(13):
977 - 978.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. R. Parulekar and E. A. Eisenhauer
Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice
J Natl Cancer Inst,
July 7, 2004;
96(13):
990 - 997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Cuccuru, C. Lanzi, G. Cassinelli, G. Pratesi, M. Tortoreto, G. Petrangolini, E. Seregni, A. Martinetti, D. Laccabue, C. Zanchi, et al.
Cellular Effects and Antitumor Activity of RET Inhibitor RPI-1 on MEN2A-Associated Medullary Thyroid Carcinoma
J Natl Cancer Inst,
July 7, 2004;
96(13):
1006 - 1014.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Merimsky, E. Gez, R. Weitzen, H. Nehushtan, R. Rubinov, H. Hayat, T. Peretz, M. Ben-Shahar, H. Biran, R. Katsenelson, et al.
Targeting pulmonary metastases of renal cell carcinoma by inhalation of interleukin-2
Ann. Onc.,
April 1, 2004;
15(4):
610 - 612.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Floyd and T. M. Mcshane
Development and Use of Biomarkers in Oncology Drug Development
Toxicol Pathol,
January 1, 2004;
32(1_suppl):
106 - 115.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. E. Johnson, T. Fischer, B. Fischer, D. Dunlop, D. Rischin, S. Silberman, M. O. Kowalski, D. Sayles, S. Dimitrijevic, C. Fletcher, et al.
Phase II Study of Imatinib in Patients with Small Cell Lung Cancer
Clin. Cancer Res.,
December 1, 2003;
9(16):
5880 - 5887.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. G. Roberts Jr, T. J. Lynch Jr, and B. A. Chabner
The Phase III Trial in the Era of Targeted Therapy: Unraveling the "Go or No Go" Decision
J. Clin. Oncol.,
October 1, 2003;
21(19):
3683 - 3695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. N. Gardner and M. Fernandes
New tools for cancer chemotherapy: computational assistance for tailoring treatments
Mol. Cancer Ther.,
October 1, 2003;
2(10):
1079 - 1084.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. B.Y. Ma, R. G. Bristow, J. Kim, and L. L. Siu
Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents
J. Clin. Oncol.,
July 15, 2003;
21(14):
2760 - 2776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Grunwald and M. Hidalgo
Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment
J Natl Cancer Inst,
June 18, 2003;
95(12):
851 - 867.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. Patrick-Miller
Is There a Role for the Assessment of Health-related Quality of Life in the Clinical Evaluation of Novel Cytostatic Agents?: Commentary re: P. M. LoRusso, Improvements in Quality of Life and Disease-related Symptoms in Phase I Trials of the Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Non-Small Cell Lung Cancer and Other Solid Tumors. Clin. Cancer Res., 9: 2040-2048, 2003.
Clin. Cancer Res.,
June 1, 2003;
9(6):
1990 - 1994.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. L. Rosner, W. Stadler, and M. J. Ratain
Randomized Discontinuation Design: Application to Cytostatic Antineoplastic Agents
J. Clin. Oncol.,
November 15, 2002;
20(22):
4478 - 4484.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Fox, G. A. Curt, and F. M. Balis
Clinical Trial Design for Target-Based Therapy
Oncologist,
October 1, 2002;
7(5):
401 - 409.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Herbst, K. R. Hess, H. T. Tran, J. E. Tseng, N. A. Mullani, C. Charnsangavej, T. Madden, D. W. Davis, D. J. McConkey, M. S. O'Reilly, et al.
Phase I Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors
J. Clin. Oncol.,
September 15, 2002;
20(18):
3792 - 3803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Herbst, A.-M. Maddox, M. L. Rothenberg, E. J. Small, E. H. Rubin, J. Baselga, F. Rojo, W. K. Hong, H. Swaisland, S. D. Averbuch, et al.
Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non-Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial
J. Clin. Oncol.,
September 15, 2002;
20(18):
3815 - 3825.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Schilsky
End Points in Cancer Clinical Trials and the Drug Approval Process
Clin. Cancer Res.,
April 1, 2002;
8(4):
935 - 938.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Marx, C. B. Steer, P. Harper, N. Pavlakis, O. Rixe, and D. Khayat
Unexpected Serious Toxicity With Chemotherapy and Antiangiogenic Combinations: Time to Take Stock!
J. Clin. Oncol.,
March 15, 2002;
20(6):
1446 - 1448.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Yokoi, J. Kuromitsu, T. Kawai, T. Nagasu, N. Hata Sugi, K. Yoshimatsu, H. Yoshino, and T. Owa
Profiling Novel Sulfonamide Antitumor Agents with Cell-based Phenotypic Screens and Array-based Gene Expression Analysis
Mol. Cancer Ther.,
February 1, 2002;
1(4):
275 - 286.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Motzer, W. Berg, M. Ginsberg, P. Russo, J. Vuky, R. Yu, J. Bacik, and M. Mazumdar
Phase II Trial of Thalidomide for Patients With Advanced Renal Cell Carcinoma
J. Clin. Oncol.,
January 1, 2002;
20(1):
302 - 306.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Kerbel
Clinical Trials of Antiangiogenic Drugs: Opportunities, Problems, and Assessment of Initial Results
J. Clin. Oncol.,
September 15, 2001;
19(90001):
45s - 51.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Ratain, W. M. Stadler, E. L. Korn, S. G. Arbuck, J. M. Pluda, R. Simon, R. S. Kaplan, and M. C. Christian
Clinical Trial Designs for Cytostatic Agents
J. Clin. Oncol.,
June 15, 2001;
19(12):
3154 - 3155.
[Full Text]
[PDF]
|
|
|
|
